ARA-290 research: trial populations, results and limits

Evidence scope: this comparison covers three selected human clinical reports. It separates populations, protocols and outcomes. It is not an exhaustive trial census, a current regulatory-status review or a dosing guide.

An ARA-290 dosage search can hide two different questions: what researchers tested, and what an individual should use. A trial can document the first without answering the second. The protocol also needs the right population attached to it.

Type 2 diabetes neuropathy: a fixed regimen

The 2014 placebo-controlled, double-blind phase 2 study enrolled people with type 2 diabetes and neuropathic symptoms. Its active regimen was 4 mg subcutaneously each day for 28 days, with another month of observation without treatment. It did not compare 1, 4 and 8 mg arms.^[1]

The report describes improvements in HbA1c and PainDetect symptoms. Its corneal nerve finding involved a subgroup with reduced nerve-fiber density at baseline. That is narrower than proof of nerve regeneration across all participants. The short observation period also cannot settle repeated-use or long-term safety.^[1]

Sarcoidosis: different dose arms and a surrogate endpoint

The 2017 randomized phase 2b trial included 64 people with sarcoidosis-associated small nerve fiber loss and neuropathic pain. It compared daily 1, 4 and 8 mg cibinetide arms with placebo over 28 days. Its primary endpoint was change in corneal nerve fiber area.^[2]

The indexed abstract reports an increase in nerve-fiber measures in the 4 mg group. Pain improved in all groups; the reported placebo-corrected pain difference in the moderate-to-severe subgroup had P = 0.157. A tissue surrogate and a statistically established pain benefit are different claims. This comparison uses the abstract and does not reproduce its numerical corneal effect estimate.^[2]

Diabetic macular edema: a separate, small pilot

A 2020 open-label phase 2 pilot studied diabetic macular edema, not the same neuropathy question. Nine participants enrolled and eight completed the study. Investigators tested 4 mg subcutaneously per day for 12 weeks, a longer protocol than the 28-day studies.^[3]

Mean visual acuity, retinal thickness, central retinal sensitivity and tear production did not improve. A patient-reported visual-function score improved, and some individuals had changes in other measures. Without a control group, with very few participants and short follow-up, those signals cannot establish efficacy. No serious adverse events or reactions were reported, which does not establish broad or long-term safety.^[3]

How to read the research without turning it into a protocol

Keep four items together: the population, the route and duration, the comparator, and the actual outcome. Do not combine different studies into a universal regimen or treat a surrogate endpoint as a demonstrated benefit for every symptom.

These selected reports do not establish effects on athletic recovery, performance or aging. They also do not establish the identity, quality or clinical suitability of a product bought online. Those are separate questions. This article does not rank ARA-290 against the entire peptide market or claim to count every human study.

For another evidence-reading resource, see the MaxHuman peptide research guide.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It does not provide treatment or dosing instructions. Consult a qualified clinician for individual medical decisions.